Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis
Open Access
- 24 July 2013
- journal article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 32 (1) , 45
Abstract
Osteopontin (OPN) plays important roles in the modulation of apoptosis, angiogenesis, immune response, and tumor invasion. Elevated osteopontin expression has been reported in the lung cancer tissues compared to counterpart normal tissues. This study examined whether genetic variations in the osteopontin gene are associated with survival of lung cancer patients and occurrence rate of bone metastasis. Three hundred and sixty patients with stages I to IV between 2003 and 2007 were recruited in this study and same number of healthy persons were used as control. Three promoter osteopontin polymorphisms, OPN-66 T/G, -156G/GG, and -443C/T variants were genotyped using DNA from blood lymphocytes. Chi-square test and a Fisher's exact test were used to analyze the genotype distribution among TNM stages and incidence of bone metastasis and lymph mode metastasis. Kaplan-Meier method and log-rank test were used to compare survival by different genotypes. For the variant at nt -443 (CC), there was a significant difference between the number of patients with stage IV and those with all other stages of lung cancer (p < 0.01). Patients with -443 (CC) variant had significant higher incidence of bone metastasis development compared to other genotypes. For the variant at nt -443 (CT), there was a significant difference between the number of lung cancer patients with stage III + IV and those with stage I + II (P < 0.01). The survival rates for patients with the C/C genotype were significantly lower than for patients with the other two genotypes (C/T, T/T). OSTEOPONTIN -443C/T polymorphism is a potential predictive marker of survival in lung cancer patients, it is correlated with bone metastasis significantly.Keywords
This publication has 32 references indexed in Scilit:
- Genetic polymorphisms in the osteopontin promoter increases the risk of distance metastasis and death in Chinese patients with gastric cancerBMC Cancer, 2012
- Expressions of osteopontin (OPN), ανβ3 and Pim-1 associated with poor prognosis in non-small cell lung cancer (NSCLC)Chinese Journal of Cancer Research, 2012
- Lower Blood Calcium Associates with Unfavorable Prognosis and Predicts for Bone Metastasis in NSCLCPLOS ONE, 2012
- Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer PatientsPLOS ONE, 2011
- A Novel 3-D Mineralized Tumor Model to Study Breast Cancer Bone MetastasisPLOS ONE, 2010
- Osteopontin: an early innate immune marker of Escherichia coli mastitis harbors genetic polymorphisms with possible links with resistance to mastitisBMC Genomics, 2009
- Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-βJournal of Clinical Investigation, 2009
- Biomarkers for DNA DSB inhibitors and radiotherapy clinical trialsCancer and Metastasis Reviews, 2008
- Bone metastasis: pathogenesis and therapeutic implicationsClinical & Experimental Metastasis, 2007
- Elevated plasma osteopontin associated with gastric cancer development, invasion and survivalGut, 2006